CST, 93852S, Olaparib (AZD2281)

Product Usage Information
Olaparib (AZD2281) is supplied as a lyophilized powder. For a 10 mM stock, reconstitute 5 mg of powder in 1.15 ml of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.
Storage
Store lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.
Background
Olaparib (AZD2281) is a potent and selective PARP-inhibitor, specifically targeting PARP1 and PARP2 (IC = 5 nM and 1 nM, respectively) (1). This small molecule has synergistic effects on breast cancer cell lines when combined with other treatments, independent of status (2). Non-small cell lung cancer (NSCLC) cancer cells that are homologous recombination (HR)-deficient are hypersensitive to Olaparib (AZD2281) treatment, resulting in reduced cell viability (3).
Alternate Names
4-(3-(4-(cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazine-1(2H)-one; AZD-2281; AZD2281; KU-0059436; KU-59436; Olaparib